← Back to patent-cliff list
海姆泊芬
Tier C — Watch / tradeHemoporfin
上海复旦张江生物医药股份有限公司
Originator
2016
First approval
-
Expiry (public)
No sales data
Peak sales
化学药
Type
Targets：Not applicable
Brand：复美达
Indications (approved)：肿瘤
Regional status
US
临床二期
2024-09-21
EU
-
China
批准上市
2016-09-29
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Hemoporfin?
Approved indications include: 肿瘤.
When does the Hemoporfin patent expire?
No public expiry year is available for Hemoporfin yet; this page updates once verified.
How do I get a quote for Hemoporfin intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-24